Equities analysts expect AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) to post sales of $930,000.00 for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for AcelRx Pharmaceuticals’ earnings, with estimates ranging from $550,000.00 to $1.30 million. AcelRx Pharmaceuticals posted sales of $2.66 million in the same quarter last year, which suggests a negative year-over-year growth rate of 65%. The company is scheduled to report its next quarterly earnings report on Tuesday, August 7th.
On average, analysts expect that AcelRx Pharmaceuticals will report full-year sales of $6.35 million for the current financial year, with estimates ranging from $1.99 million to $10.70 million. For the next financial year, analysts expect that the business will post sales of $23.07 million per share, with estimates ranging from $17.40 million to $28.74 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research firms that that provide coverage for AcelRx Pharmaceuticals.
AcelRx Pharmaceuticals (NASDAQ:ACRX) last released its earnings results on Wednesday, May 9th. The specialty pharmaceutical company reported ($0.23) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.01. The business had revenue of $0.34 million during the quarter, compared to the consensus estimate of $0.78 million.
Several institutional investors and hedge funds have recently made changes to their positions in the company. GSA Capital Partners LLP bought a new position in shares of AcelRx Pharmaceuticals in the 1st quarter valued at about $113,000. Northern Trust Corp grew its position in shares of AcelRx Pharmaceuticals by 60.8% in the 1st quarter. Northern Trust Corp now owns 91,481 shares of the specialty pharmaceutical company’s stock valued at $192,000 after acquiring an additional 34,584 shares during the period. Geller Family Office Services LLC grew its position in shares of AcelRx Pharmaceuticals by 175.0% in the 4th quarter. Geller Family Office Services LLC now owns 275,000 shares of the specialty pharmaceutical company’s stock valued at $557,000 after acquiring an additional 175,000 shares during the period. Finally, Virtu Financial LLC bought a new position in shares of AcelRx Pharmaceuticals in the 4th quarter valued at about $120,000. 8.40% of the stock is owned by institutional investors.
AcelRx Pharmaceuticals stock traded up $0.23 during mid-day trading on Monday, reaching $4.13. The company’s stock had a trading volume of 994,112 shares, compared to its average volume of 503,621. The company has a market cap of $187.32 million, a P/E ratio of -3.75 and a beta of 2.36. AcelRx Pharmaceuticals has a 12 month low of $1.55 and a 12 month high of $5.75. The company has a current ratio of 4.05, a quick ratio of 4.00 and a debt-to-equity ratio of -0.20.
About AcelRx Pharmaceuticals
AcelRx Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company also develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AcelRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.